SMART-JIA
SMART-JIA
A Smart Solution
for Kids with JIA
A Smart Solution for Kids with JIA
A Smart Solution
for Kids with JIA
The SMART-JIA trial is for children with juvenile idiopathic arthritis (JIA) who have already tried a common treatment called a biologic—a type of medicine made from living cells that helps regulate the immune system— but didn’t see the results they needed. When that first treatment doesn’t work, there are still many options, but it’s not always clear which one to try next. That’s where this study comes in.
The SMART-JIA trial is for children with juvenile idiopathic arthritis (JIA) who have already tried a common treatment called a biologic—a type of medicine made from living cells that helps regulate the immune system— but didn’t see the results they needed. When that first treatment doesn’t work, there are still many options, but it’s not always clear which one to try next. That’s where this study comes in.
Our goal is to improve the long term health and quality of life for kids living with JIA by giving doctors better tools to make the right treatment decisions.
Our goal is to improve the long term health and quality of life for kids living with JIA by giving doctors better tools to make the right treatment decisions.
Who is Eligible to Join?
Anyone who has been diagnosed with JIA
Anyone between 2-18 years of age
Anyone who has taken a biologic medication that has proved unsuccessful.
Anyone who has been diagnosed with JIA
Anyone between 2-18 years of age
Anyone who has taken a biologic medication that has proved unsuccessful.
There may be additional criteria that your child must meet to join the study, which will be confirmed by the study team and your child’s rheumatologist. Learn more below.
There may be additional criteria that your child must meet to join the study, which will be confirmed by the study team and your child’s rheumatologist. Learn more below.
Explore the Trial
Randomization
What is randomization?
Randomization assigns treatments by chance, not by choice. This process is used in clinical trials to help make results fair and unbiased.
Trial Begins
First Study Medication
TNFi
A TNFi (Tumor Necrosis Factor Inhibitor) is a biologic drug that blocks a protein that causes inflammation and swelling. In the trial, we use a different TNFi medication after your child’s initial TNFi treatment didn’t work well or caused side effects.
IL-6i
A medication that blocks the interleukin-6 (IL-6) protein, which causes inflammation in various diseases like JIA.
Abatacept
A medication to treat JIA that works by blocking the activity of T cells, which are immune cells that play a role in inflammation.
JAKi
A class of drugs used to treat JIA and other inflammatory conditions, working by blocking Janus kinase (JAKi) enzymes that lead to inflammation.
Working?
Great! As long as your child's medication is working, they will stay on that medication until the end of the trial.
Not Working?
Continue to Randomization 2
Randomization 2
What happens at this stage?
If the first medication didn’t help your child, the study team will look at other options that may work better. This second randomization step helps the team see which medications manage symptoms best, allowing us to tailor your child’s care even further and improve long-term outcomes.
Start Second Random Trial Medication
The second study medication will be based off of the previous medication that was used.
Measure Response
What are we looking for at this point?
Your child’s study team is looking to see how well the medication is working to treat your child’s arthritis. The team will also look for safety issues or problems with the medication.
Check-Ins With Your Doctor | At 3-6 Months
End
What happens at this stage?
The study team will consider how much your child’s condition has improved after a year. They will also evaluate any safety issues or problems.
Trial End | At 12 Months
The study ends, but your child’s treatment and collaboration do not. You will have a follow-up phone call to make sure that your child isn’t experiencing any unexpected side effects from the medication. You will also continue to work with your child’s rheumatologist and care team to determine what comes next.
Post Trial | Ongoing
Randomization
What is randomization?
Randomization assigns treatments by chance, not by choice. This process is used in clinical trials to help make results fair and unbiased.
Trial Begins
First Study Medication
TNFi
A TNFi (Tumor Necrosis Factor Inhibitor) is a biologic drug that blocks a protein that causes inflammation and swelling. In the trial, we use a different TNFi medication after your child’s initial TNFi treatment didn’t work well or caused side effects.
IL-6i
A medication that blocks the interleukin-6 (IL-6) protein, which causes inflammation in various diseases like JIA.
Abatacept
A medication to treat JIA that works by blocking the activity of T cells, which are immune cells that play a role in inflammation.
JAKi
A class of drugs used to treat JIA and other inflammatory conditions, working by blocking Janus kinase (JAKi) enzymes that lead to inflammation.
Working?
Great! As long as your child's medication is working, they will stay on that medication until the end of the trial.
Not Working?
Continue to Randomization 2
Randomization 2
What happens at this stage?
If the first medication didn’t help your child, the study team will look at other options that may work better. This second randomization step helps the team see which medications manage symptoms best, allowing us to tailor your child’s care even further and improve long-term outcomes.
Start Second Random Trial Medication
The second study medication will be based off of the previous medication that was used.
Measure Response
What are we looking for at this point?
Your child’s study team is looking to see how well the medication is working to treat your child’s arthritis. The team will also look for safety issues or problems with the medication.
Check-Ins With Your Doctor | At 3-6 Months
End
What happens at this stage?
The study team will consider how much your child’s condition has improved after a year. They will also evaluate any safety issues or problems.
Trial End | At 12 Months
The study ends, but your child’s treatment and collaboration do not. You will have a follow-up phone call to make sure that your child isn’t experiencing any unexpected side effects from the medication. You will also continue to work with your child’s rheumatologist and care team to determine what comes next.
Post Trial | Ongoing
Randomization
What is randomization?
Randomization assigns treatments by chance, not by choice. This process is used in clinical trials to help make results fair and unbiased.
Trial Begins
First Study Medication
TNFi
A TNFi (Tumor Necrosis Factor Inhibitor) is a biologic drug that blocks a protein that causes inflammation and swelling. In the trial, we use a different TNFi medication after your child’s initial TNFi treatment didn’t work well or caused side effects.
IL-6i
A medication that blocks the interleukin-6 (IL-6) protein, which causes inflammation in various diseases like JIA.
Abatacept
A medication to treat JIA that works by blocking the activity of T cells, which are immune cells that play a role in inflammation.
JAKi
A class of drugs used to treat JIA and other inflammatory conditions, working by blocking Janus kinase (JAKi) enzymes that lead to inflammation.
Working?
Great! As long as your child's medication is working, they will stay on that medication until the end of the trial.
Not Working?
Continue to Randomization 2
Randomization 2
What happens at this stage?
If the first medication didn’t help your child, the study team will look at other options that may work better. This second randomization step helps the team see which medications manage symptoms best, allowing us to tailor your child’s care even further and improve long-term outcomes.
Start Second Random Trial Medication
The second study medication will be based off of the previous medication that was used.
Measure Response
What are we looking for at this point?
Your child’s study team is looking to see how well the medication is working to treat your child’s arthritis. The team will also look for safety issues or problems with the medication.
Check-Ins With Your Doctor | At 3-6 Months
End
What happens at this stage?
The study team will consider how much your child’s condition has improved after a year. They will also evaluate any safety issues or problems.
Trial End | At 12 Months
The study ends, but your child’s treatment and collaboration do not. You will have a follow-up phone call to make sure that your child isn’t experiencing any unexpected side effects from the medication. You will also continue to work with your child’s rheumatologist and care team to determine what comes next.
Post Trial | Ongoing
Randomization
What is randomization?
Randomization assigns treatments by chance, not by choice. This process is used in clinical trials to help make results fair and unbiased.
Trial Begins
First Study Medication
TNFi
A TNFi (Tumor Necrosis Factor Inhibitor) is a biologic drug that blocks a protein that causes inflammation and swelling. In the trial, we use a different TNFi medication after your child’s initial TNFi treatment didn’t work well or caused side effects.
IL-6i
A medication that blocks the interleukin-6 (IL-6) protein, which causes inflammation in various diseases like JIA.
Abatacept
A medication to treat JIA that works by blocking the activity of T cells, which are immune cells that play a role in inflammation.
JAKi
A class of drugs used to treat JIA and other inflammatory conditions, working by blocking Janus kinase (JAKi) enzymes that lead to inflammation.
Working?
Great! As long as your child's medication is working, they will stay on that medication until the end of the trial.
Not Working?
Continue to Randomization 2
Randomization 2
What happens at this stage?
If the first medication didn’t help your child, the study team will look at other options that may work better. This second randomization step helps the team see which medications manage symptoms best, allowing us to tailor your child’s care even further and improve long-term outcomes.
Start Second Random Trial Medication
The second study medication will be based off of the previous medication that was used.
Measure Response
What are we looking for at this point?
Your child’s study team is looking to see how well the medication is working to treat your child’s arthritis. The team will also look for safety issues or problems with the medication.
Check-Ins With Your Doctor | At 3-6 Months
End
What happens at this stage?
The study team will consider how much your child’s condition has improved after a year. They will also evaluate any safety issues or problems.
Trial End | At 12 Months
The study ends, but your child’s treatment and collaboration do not. You will have a follow-up phone call to make sure that your child isn’t experiencing any unexpected side effects from the medication. You will also continue to work with your child’s rheumatologist and care team to determine what comes next.
Post Trial | Ongoing
Quick Links
Quick Links
Quick Links
Quick Links
Quick Links
Phone number
+1 234 456 7891
contact@smartjia.com
Legal
Privacy Policy
Cookie Policy
Data Policy
Quick links
Caregivers
Patients
FAQ
Get Updates
